- Home
- CDT vs LGHL Comparison
CDT vs LGHL Comparison
Compare CDT & LGHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDT
- LGHL
- Stock Information
- Founded
- CDT 2019
- LGHL 2015
- Country
- CDT United States
- LGHL Singapore
- Employees
- CDT N/A
- LGHL N/A
- Industry
- CDT Biotechnology: Pharmaceutical Preparations
- LGHL Investment Bankers/Brokers/Service
- Sector
- CDT Health Care
- LGHL Finance
- Exchange
- CDT Nasdaq
- LGHL Nasdaq
- Market Cap
- CDT 3.1M
- LGHL 3.3M
- IPO Year
- CDT N/A
- LGHL N/A
- Fundamental
- Price
- CDT $2.15
- LGHL $7.40
- Analyst Decision
- CDT
- LGHL
- Analyst Count
- CDT 0
- LGHL 0
- Target Price
- CDT N/A
- LGHL N/A
- AVG Volume (30 Days)
- CDT 57.3K
- LGHL 13.0K
- Earning Date
- CDT 11-14-2025
- LGHL 01-01-0001
- Dividend Yield
- CDT N/A
- LGHL N/A
- EPS Growth
- CDT N/A
- LGHL N/A
- EPS
- CDT N/A
- LGHL N/A
- Revenue
- CDT N/A
- LGHL N/A
- Revenue This Year
- CDT N/A
- LGHL N/A
- Revenue Next Year
- CDT N/A
- LGHL N/A
- P/E Ratio
- CDT N/A
- LGHL N/A
- Revenue Growth
- CDT N/A
- LGHL N/A
- 52 Week Low
- CDT $1.61
- LGHL $3.93
- 52 Week High
- CDT $2,198.40
- LGHL $213.20
- Technical
- Relative Strength Index (RSI)
- CDT 47.44
- LGHL 91.64
- Support Level
- CDT $1.61
- LGHL $0.30
- Resistance Level
- CDT $2.84
- LGHL $0.93
- Average True Range (ATR)
- CDT 0.21
- LGHL 0.24
- MACD
- CDT -0.08
- LGHL 0.41
- Stochastic Oscillator
- CDT 39.19
- LGHL 95.79
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
About LGHL Lion Group Holding Ltd.
Lion Group Holding Ltd is an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, Hong Kong-based Over-The-Counter (OTC) stock options trading business, and futures and securities brokerage services. It provides these services through its Lion Brokers Pro and a variety of other applications. The company generates a majority of its revenue from its CFD trading services business. Geographically, the firm's key revenue-generating market is Hong Kong.